{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:01:05Z","timestamp":1793948465735,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.eclinm.2024.102838","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:10:31Z","timestamp":1727183431000},"page":"102838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials \u2013 insights from an expert virtual roundtable"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Lee Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-7439","authenticated-orcid":false,"given":"Emily","family":"Alger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Collis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Gnanasakthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kamudoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kholmanskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellinda L.","family":"King-Kallimanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0996-7081","authenticated-orcid":false,"given":"Joan","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3918-1174","authenticated-orcid":false,"given":"Claire","family":"Piccinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija Rerhou","family":"Rantell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaeha","family":"Rauz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-8386","authenticated-orcid":false,"given":"Ameeta","family":"Retzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7307-3306","authenticated-orcid":false,"given":"Maxime","family":"Sasseville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley K.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-7306","authenticated-orcid":false,"given":"Roger","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-7881","authenticated-orcid":false,"given":"John Devin","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2024.102838_bib1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.molonc.2014.07.025","article-title":"Early phase clinical trials to identify optimal dosing and safety","volume":"9","author":"Cook","year":"2015","journal-title":"Mol Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102838_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clon.2017.10.005","article-title":"Early phase clinical trial designs \u2013 state of play and adapting for the future","volume":"29","author":"Harrington","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102838_bib3","article-title":"Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102838_bib4","series-title":"Guidelines for phase I clinical trials","year":"2018"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102838_bib5","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1002\/cam4.4307","article-title":"Trends in patient-reported outcome use in early phase dose-finding oncology trials \u2013 an analysis of ClinicalTrials.gov","volume":"10","author":"Lai-Kwon","year":"2021","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.eclinm.2024.102838_bib6","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2024.102838_bib7","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102838_bib8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Maio","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102838_bib9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djab015","article-title":"Underreporting of symptomatic adverse events in phase I clinical trials","volume":"113","author":"Veitch","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102838_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of low- and moderate-grade adverse events in patients' treatment experience and treatment discontinuation: an analysis of the E1912 trial","volume":"42","author":"O'Connell","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102838_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41591-021-01648-4","article-title":"The value of patient-reported outcomes in early-phase clinical trials","volume":"28","author":"Retzer","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102838_bib12","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2014.04.031","volume":"50","author":"Postel-Vinay","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2024.102838_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102228","article-title":"Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review","volume":"64","author":"Alger","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102838_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/sim.8402","article-title":"Incorporating patient-reported outcomes in dose-finding clinical trials","volume":"39","author":"Lee","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2024.102838_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19466315.2023.2288013","article-title":"Isotonic phase I cancer clinical trial design utilizing patient-reported outcomes","author":"Wages","year":"2024","journal-title":"Stat Biopharm Res"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102838_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103626","article-title":"U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes","volume":"9","author":"Alger","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2024.102838_bib17","first-page":"1","article-title":"Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment","author":"Andrillon","year":"2023","journal-title":"J\u00a0Biopharm Stat"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102838_bib18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/oncolo\/oyac117","article-title":"Using patient-reported outcomes in dose-finding oncology trials: surveys of key stakeholders and the national cancer research Institute consumer forum","volume":"27","author":"Lai-Kwon","year":"2022","journal-title":"Oncologist"},{"issue":"30","key":"10.1016\/j.eclinm.2024.102838_bib20","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Zirkelbach","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.eclinm.2024.102838_bib21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology \u2014 when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102838_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.annonc.2022.09.158","article-title":"Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022","volume":"34","author":"Araujo","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102838_bib23","series-title":"Core patient-reported outcomes in cancer clinical trials guidance for industry","year":"2021"},{"key":"10.1016\/j.eclinm.2024.102838_bib24","series-title":"Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of patient-reported outcome (PRO) measures in oncology studies","year":"2016"},{"key":"10.1016\/j.eclinm.2024.102838_bib50","series-title":"Broadening the Definition of Tolerability in Cancer Clinical Trials to Capture the Patient Experience","author":"Basch","year":"2020"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102838_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/djab017","article-title":"Patient-reported outcomes for tolerability assessment in phase I cancer clinical trials","volume":"113","author":"Basch","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102838_bib26","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jval.2023.06.006","article-title":"Assessment of patient-reported outcomes in industry-sponsored phase I oncology studies: considerations for translating theory into practice","volume":"26","author":"Gnanasakthy","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.eclinm.2024.102838_bib27","series-title":"National cancer Institute community oncology research program (NCORP) program guidelines: Part 3: development of NCORP concepts, protocols, and amendments and inclusion of HRQOL in NCTN treatment trials","year":"2022"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102838_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40900-024-00599-7","article-title":"Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs","volume":"10","author":"Alger","year":"2024","journal-title":"Res Involv Engagem"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102838_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s41687-022-00444-z","article-title":"Inclusion of patient-reported outcome instruments in US FDA medical device marketing authorizations","volume":"6","author":"Matts","year":"2022","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102838_bib31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2024.102838_bib32","series-title":"Supporting a patient-centric approach to dose optimization in oncology: the essential role of patient-reported outcomes (PROs)","year":"2022"},{"issue":"19","key":"10.1016\/j.eclinm.2024.102838_bib33","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1001\/jama.2022.6421","article-title":"Ethical considerations for the inclusion of patient-reported outcomes in clinical research: the PRO ethics guidelines","volume":"327","author":"Cruz Rivera","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102838_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102838_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102838_bib36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-022-09817-5","article-title":"Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study","volume":"22","author":"Kennedy","year":"2022","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102838_bib37","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/jnci\/djac128","article-title":"Listening to the patient voice adds value to cancer clinical trials","volume":"114","author":"Brundage","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102838_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s41687-023-00634-3","article-title":"Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial","volume":"7","author":"McMullan","year":"2023","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102838_bib39","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/s13063-020-04745-w","article-title":"On behalf of the EQoLG. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial","volume":"21","author":"Wintner","year":"2020","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102838_bib40","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41416-023-02307-w","article-title":"A\u00a0tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events","volume":"129","author":"Janse van Rensburg","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2024.102838_bib41","article-title":"Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): rasch analysis","volume":"377","author":"Hughes","year":"2022","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102838_bib42","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102838_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","article-title":"Recommendations to address respondent burden associated with patient-reported outcome assessment","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102838_bib44","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/S1470-2045(22)00654-4","article-title":"Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group","volume":"24","author":"Piccinin","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102838_bib45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jamia\/ocy169","article-title":"Patient free text reporting of symptomatic adverse events in cancer clinical research using the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"26","author":"Chung","year":"2019","journal-title":"J\u00a0Am Med Inform Assoc"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102838_bib46","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1016\/S1470-2045(20)30319-3","article-title":"Demystifying the estimand framework: a case study using patient-reported outcomes in oncology","volume":"21","author":"Fiero","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102838_bib47","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102838_bib48","series-title":"Core patient-reported outcomes set for early phase dose-finding oncology trials","author":"Core Outcome Measures in Effectiveness Trials","year":"2024"},{"key":"10.1016\/j.eclinm.2024.102838_bib49","series-title":"FDA workshop: 9th annual clinical outcome assessment in cancer clinical trials workshop","year":"2024"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:09:17Z","timestamp":1732061357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024004176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":48,"alternative-id":["S2589537024004176"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102838","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials \u2013 insights from an expert virtual roundtable","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102838"}}